Who are umeclidinium 62.5 µg and vilanterol 25 µg's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/umeclidinium-62-5-g-and-vilanterol-25-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

umeclidinium 62.5 µg and vilanterol 25 µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

umeclidinium 62.5 µg and vilanterol 25 µg (umeclidinium 62.5 µg and vilanterol 25 µg) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA). Area: Respiratory/Pulmonology.

marketed Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

umeclidinium 62.5 µg and vilanterol 25 µg (umeclidinium 62.5 µg and vilanterol 25 µg) — University of Tennessee Graduate School of Medicine. Umeclidinium is a long-acting anticholinergic that blocks muscarinic M3 receptors in airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors, together producing bronchodilation for maintenance treatment of chronic obstructive pulmonary disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
umeclidinium 62.5 µg and vilanterol 25 µg TARGET	umeclidinium 62.5 µg and vilanterol 25 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA) class)

University of Tennessee Graduate School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). umeclidinium 62.5 µg and vilanterol 25 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/umeclidinium-62-5-g-and-vilanterol-25-g. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab